Meadow Creek Investment Management’s Sage Therapeutics SAGE Stock Holding History

Meadow Creek Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$254K	Hold	1,808	–	–	0.01%	953
2019 Q2	$331K	Buy	1,808 +80	+5%	+$13.7K	0.01%	866
2019 Q1	$275K	Buy	1,728 +224	+15%	+$32.4K	0.01%	906
2018 Q4	$144K	Sell	1,504 -96	-6%	-$11K	﹤0.01%	1063
2018 Q3	$226K	Buy	1,600 +1,280	+400%	+$198K	﹤0.01%	1036
2018 Q2	$50K	Buy	320 +304	+1,900%	+$47.7K	﹤0.01%	1257
2018 Q1	$3K	Buy	+16	New	+$2.72K	﹤0.01%	1324

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Meadow Creek Investment Management's SAGE Position: Q3 2019 in Review

Meadow Creek Investment Management held its Sage Therapeutics (SAGE) position steady in Q3 2019 at 1,808 shares worth $254K. The position accounts for 0.01% of the portfolio, ranked #953.

Meadow Creek Investment Management first reported a position in SAGE in Q1 2018 and has held it in 7 quarters since. The position peaked at $331K in Q2 2019. 285 funds tracked by Wall St. Rank hold SAGE as of Q3 2019.

Meadow Creek Investment Management held 1,808 shares of Sage Therapeutics worth $254K as of Q3 2019.
Meadow Creek Investment Management left its Sage Therapeutics share count unchanged in Q3 2019.
Sage Therapeutics made up 0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #953 holding.
Meadow Creek Investment Management first reported a position in Sage Therapeutics in Q1 2018 and has held it in 7 quarters since.
Meadow Creek Investment Management's Sage Therapeutics position peaked at $331K in Q2 2019.
285 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.